Dr. Platt is a world-renowned expert in carbohydrate chemistry who has founded three publicly traded companies, creating nearly $1B for investors. He has raised $150M directly in public markets in the U.S., and has led development of two drug candidates from concept through phase II clinical trials. Prior to Oxygen Therapeutics Inc. Dr. Platt founded Boston Therapeutics Inc. in 2010 (OTC: BTHE). Between 2001 and 2009, Dr. Platt became a founder of Pro-Pharmaceuticals, Inc. (OTC: PRWP and AMEX: PRW, now NASDAQ: GALT), and served as its chief executive officer and board chairman. In 1995 Dr. Platt founded International Gene Group (NASDAQ: IGGI, GLGS now LPJC); he continued to serve the firm through 2000.
Mr. Kwintner is an experienced entrepreneur and business executive with proven capabilities and success in both established organizations and start-up ventures. He is experienced in developing and implementing innovative business strategies, securing investment opportunities and financing and handling all aspects of company operations and corporate transactions. Mr. Kwintner was the founder of two successful start-up companies. He was the President of BananaLogix Inc., an emerging company in the nutraceuticals space that developed a unique all-natural supplement that significantly reduced high blood pressure without the side effects of traditional hypertension drugs. He was also the CEO of VeriBrands LLC, a distributor of a full line of high-quality medical devices. Prior to that, Mr. Kwintner was a Strategic Planning Manager at Way Systems, Inc., a pioneer in mobile POS solutions and gateway services for mobile merchants, which was later acquired by Verifone. Mr. Kwintner began his career as an industrial engineer in the Israeli Navy and subsequently practiced business and corporate law in Israel. Mr. Kwintner earned an M.S. in Management of Technology (MBA equivalent) from MIT Sloan School of Management, an LL.B. from Tel Aviv University School of Law and a B.S. in Industrial Engineering & Management from the Technion – Israel Institute of Technology.
Benjamin Rivnay, PhD, is Chief Scientist. In this role, Dr. Rivnay is responsible for the development of the company’s science and technology. He serves as the primary liaison with the company’s medical advisory board and reports to Rom E. Eliaz, PhD, and chairman of the Board of Directors’ Scientific Advisory Committee.
Dr. Rivnay is a seasoned director of R&D within the biotechnology industry. Most recently, he was Director of Research and Development at Formatech Inc., where he managed more than 50 projects on formulation development for a diverse group of drugs, as well as studies of stability and material compatibility, initial engineering and process development activities, and preparation of non-cGMP product lots for toxicology studies and other research purposes. Earlier, he was Vice President of Research and Development and Lab Director at Repromedix Corporation, where he introduced more than 50 new test products for both male and female infertility. Before Repromedix, he served as Senior Investigator and Program Leader at Procept Inc., where he initiated and led a new R&D program focusing on the development of anti-allergic drugs, and as Senior Scientist at Neurex Corporation. He holds a PhD in biochemistry from The Weizmann Institute of Science and a BSc in biology from Tel Aviv University.
Mr. Soderquist has more than 30 years of senior international entrepreneurial management experience within technology companies. He has served in CFO and other managerial capacities in multiple industry sectors and companies, such as Industrivarden (OMX:INDU), Electrolux (OMX:ELUX), Ericsson (NASDAQ:ERIC), Swedish Match (OMX:SWMA) and SKF AB (OMX:SKF), and most recently in Belden (NYSE: BDC) and Traction (OMX:TRAC). Ola is a multi-lingual senior finance professional poised to work globally and cross-functionally, particularly with complex projects involving business integration, systems implementation, continuous improvement, and process excellence. Ola’s managerial experience portfolio includes; Start-ups, Private, Public, Venture Capital and Private Equity ownership. He obtained a BS and an MS in Accounting from Stockholm School of Economics and an MBA from Babson College – Franklin W. Olin Graduate School of Business.